secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2026-05-13T20:03:04+00:00
Accession:  0001193125-26-221574
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS expands Medicare coverage for Personalis' NeXT Personal test to immunotherapy monitoring
--------------------------------------------------------------------------------

- CMS coverage now includes immunotherapy monitoring for late-stage solid tumor patients as of May 12, 2026.
- NeXT Personal is an ultrasensitive liquid biopsy test; the expanded indication broadens the addressable patient population.
- No financial impact or revenue guidance was disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526221574/0001193125-26-221574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526221574/psnl-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer